TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation: Preparation of the amorphous mirabegron (A1): involves (a) providing a solution of mirabegron in a solvent or mixture of solvents; (b) removing solvent from the solution obtained in step (a), and (c) isolating an amorphous form of mirabegron. Preferred Method: The method (M1) involves dissolving mirabegron in a mixture of methanol and water to provide a solution, cooling the obtained solution, and isolating alpha -form crystal of mirabegron. The method (M2) involves dissolving mirabegron in acetone to provide a solution, adding the obtained solution to methylcyclohexane, and isolating alpha -form crystal of mirabegron.    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: The carrier is at least one selected from gelatines, ovalbumin, soybean proteins, gum arabic, non-sucrose fatty acid esters, starches, modified starches, cellulose, methylcellulose (MC), ethylcellulose (EC), hydroxy ethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), polycarbophil, polyethylene glycol (PEG), polyethylene oxides, polyoxyalkylene derivatives, polymethacrylates, polyvinyl pyrrolidone (PVP, povidone), polyvinyl acetate (PVAc), PVP-vinylacetate-copolymer (PVP-VA), Kollidon VA 64 (RTM: a vinylpyrrolidone-vinyl acetate copolymer), lactose, sorbitol, mannitol, maltitol, saccharose, Isomalt, cyclodextrins such as alpha -cyclodextrins, beta -cyclodextrins, gamma -cyclodextrins and hydroxyl-propyl-3-cyclodextrins, sodiumcarboxymethylcellulose, sodium alginate, xantham gum, caavageenan, locust bean gum (ceratonia), chitosan, guar gum, cross-linked high amylase starch, and cross-linked polyacrylic acid (carbopol) (preferably povidone). The ratio of at least carrier to the mirabegron is at least 1:2 (wt./wt.) to (2:1) (wt./wt.). ACTIVITY - Uropathic. No biological data given.    MECHANISM OF ACTION - beta -3 Adrenoceptor agonist.    ADMINISTRATION - Administration is oral or by injection. No dosage details given.    EXAMPLE - Mirabegron (1 g) and acetone (160 ml) were charged in to a round-bottom flask at 25-35 degrees C. The contents were heated to 40-53 degrees C and stirred to dissolve mirabegron completely. The resulting solution was evaporated completely in rotary evaporator at 40-45 degrees C under reduced pressure to obtain an amorphous form of mirabegron (800 mg).